Vigil Neuroscience (NASDAQ:VIGL) Price Target Lowered to $13.00 at Wedbush

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) had its target price dropped by equities researchers at Wedbush from $24.00 to $13.00 in a report released on Friday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Wedbush also issued estimates for Vigil Neuroscience's FY2029 earnings at $1.40 EPS.

Other equities analysts have also issued research reports about the stock. Guggenheim restated a "buy" rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. JMP Securities restated a "market outperform" rating and set a $22.00 target price on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. HC Wainwright dropped their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating for the company in a research report on Friday. Finally, William Blair started coverage on shares of Vigil Neuroscience in a research report on Wednesday, December 4th. They set an "outperform" rating for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $16.25.

Vigil Neuroscience Stock Performance

Shares of NASDAQ VIGL traded down $0.01 during midday trading on Friday, reaching $1.97. The stock had a trading volume of 284,357 shares, compared to its average volume of 468,780. The stock has a 50-day moving average of $2.34 and a 200-day moving average of $2.77. The company has a market capitalization of $80.53 million, a price-to-earnings ratio of -0.96 and a beta of 1.82. Vigil Neuroscience has a 12-month low of $1.49 and a 12-month high of $6.06.

Remove Ads

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.08). As a group, analysts forecast that Vigil Neuroscience will post -2.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Vigil Neuroscience

Institutional investors have recently bought and sold shares of the business. abrdn plc lifted its position in Vigil Neuroscience by 124.9% during the fourth quarter. abrdn plc now owns 528,472 shares of the company's stock valued at $898,000 after purchasing an additional 293,461 shares during the last quarter. Geode Capital Management LLC lifted its position in Vigil Neuroscience by 41.9% during the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company's stock valued at $769,000 after purchasing an additional 66,712 shares during the last quarter. Verition Fund Management LLC bought a new stake in shares of Vigil Neuroscience in the 3rd quarter worth about $442,000. Walleye Capital LLC lifted its holdings in shares of Vigil Neuroscience by 334.4% in the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company's stock worth $407,000 after acquiring an additional 92,217 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Vigil Neuroscience by 7.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company's stock worth $5,440,000 after acquiring an additional 115,000 shares during the last quarter. Institutional investors own 83.64% of the company's stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.